Create Free Account

By creating account you will get access to hot stocks & personalised emails

Takeda Pharmaceutical Co. Ltd.

Healthcare US TKPHF

25.38USD
-(-%)

Last update at 2024-12-18T20:00:00Z

Day Range

27.6027.60
LowHigh

52 Week Range

26.2533.04
LowHigh

Fundamentals

  • Previous Close 25.38
  • Market Cap44270.07M
  • Volume100
  • P/E Ratio32.60
  • Dividend Yield4.96%
  • EBITDA1196729.04M
  • Revenue TTM4154414.07M
  • Revenue Per Share TTM2667.57
  • Gross Profit TTM 2441698.00M
  • Diluted EPS TTM0.86

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 375090.00M 302571.00M 366235.00M -60754.00000M 94896.00M
Minority interest -21.00000M -107.00000M 4140.00M 4003.00M 4006.00M
Net income 317017.00M 230059.00M 376005.00M 44241.00M 109126.00M
Selling general administrative 997309.00M 886361.00M 875663.00M 964737.00M 717599.00M
Selling and marketing expenses - - - - -
Gross profit 2783406.00M 2462160.00M 2203504.00M 2201424.00M 1437534.00M
Reconciled depreciation 664400.00M 583151.00M 559671.00M 583649.00M 272446.00M
Ebit 544788.00M 469178.00M 614866.00M 104252.00M 103937.00M
Ebitda 1209188.00M 1052329.00M 1174537.00M 687901.00M 376383.00M
Depreciation and amortization 664400.00M 583151.00M 559671.00M 583649.00M 272446.00M
Non operating income net other - - - - 0.00000M
Operating income 490505.00M 460844.00M 509269.00M 100408.00M 204969.00M
Other operating expenses 3536972.00M 3108161.00M 2688543.00M 3190780.00M 1936859.00M
Interest expense 169698.00M 166607.00M 248631.00M 165006.00M 48158.00M
Tax provision 58052.00M 72405.00M -9936.00000M -105044.00000M -14118.00000M
Interest income 62913.00M 23700.00M 105521.00M 11202.00M 6619.00M
Net interest income -106785.00000M -142907.00000M -143110.00000M -146649.00000M -60959.00000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 58052.00M 72405.00M -9936.00000M -105044.00000M -14118.00000M
Total revenue 4027478.00M 3569006.00M 3197812.00M 3291188.00M 2097224.00M
Total operating expenses 2292900.00M 2001315.00M 1694235.00M 2101016.00M 1277169.00M
Cost of revenue 1244072.00M 1106846.00M 994308.00M 1089764.00M 659690.00M
Total other income expense net -8630.00000M -15367.00000M 76.00M -23987.00000M -4510.00000M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 317038.00M 230166.00M 376171.00M 44290.00M 109014.00M
Net income applicable to common shares - 230059.00M 376005.00M 44241.00M 135192.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 13957750.00M 13178018.00M 12912293.00M 12821094.00M 13872322.00M
Intangible assets 4269657.00M 3818544.00M 3909106.00M 4171361.00M 4860368.00M
Earning assets - - - - -
Other current assets 160867.00M 141098.00M 122789.00M 114196.00M 109666.00M
Total liab 7603079.00M 7494495.00M 7735116.00M 8093608.00M 8708734.00M
Total stockholder equity 6354122.00M 5683019.00M 5173037.00M 4723483.00M 5159582.00M
Deferred long term liab - - - - 0.00000M
Other current liab 1493107.00M 1425440.00M 1407185.00M 1270265.00M 1313637.00M
Common stock 1676345.00M 1676263.00M 1668145.00M 1668123.00M 1643585.00M
Capital stock 1676345.00M 1676263.00M 1668145.00M 1668123.00M 1643585.00M
Retained earnings 1541146.00M 1479716.00M 1509906.00M 1369972.00M 1569365.00M
Other liab 544129.00M 795986.00M 962497.00M 1082848.00M 1110462.00M
Good will 4790723.00M 4407749.00M 4033917.00M 4012528.00M 4161403.00M
Other assets 709011.00M 678704.00M 689992.00M 674069.00M 368200.00M
Cash 533530.00M 849695.00M 966222.00M 637614.00M 702093.00M
Cash and equivalents - - - - -
Total current liabilities 2481940.00M 2145730.00M 1773176.00M 2175898.00M 2510931.00M
Current deferred revenue 740737.00M 644420.00M 616481.00M 587983.00M 627264.00M
Net debt 3848811.00M 3495716.00M 3669149.00M 4455690.00M 5048858.00M
Short term debt 339600.00M 203993.00M 22153.00M 586817.00M 984946.00M
Short long term debt 339600.00M 203993.00M 22153.00M 586817.00M 984946.00M
Short long term debt total 4382341.00M 4345411.00M 4635371.00M 5093304.00M 5750951.00M
Other stockholder equity 3136631.00M 2527040.00M 1994986.00M 1685388.00M 1946632.00M
Property plant equipment - 1582800.00M 1453917.00M 1386370.00M 1331931.00M
Total current assets 2397956.00M 2593642.00M 2712893.00M 2469432.00M 3050658.00M
Long term investments 378857.00M 330133.00M 348350.00M 369455.00M 306899.00M
Net tangible assets - -2543274.00000M -2769986.00000M -3460406.00000M -3809435.00000M
Short term investments 20174.00M 25305.00M 36598.00M 15822.00M 23276.00M
Net receivables 681693.00M 724377.00M 812714.00M 784921.00M 749119.00M
Long term debt 4042741.00M 4141418.00M 4613218.00M 4506487.00M 4766005.00M
Inventory 986457.00M 853167.00M 753881.00M 759599.00M 986744.00M
Accounts payable 649233.00M 516297.00M 343838.00M 318816.00M 212348.00M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 63325.00M 82611.00M 100341.00M 103846.00M 87472.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 11559794.00M 10584376.00M 10199400.00M 10351662.00M 10821664.00M
Capital lease obligations - - - - 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -607102.00000M 8580.00M 62008.00M 41851.00M 47936.00M
Change to liabilities 0.00000M 125157.00M 36620.00M -29932.00000M -16413.00000M
Total cashflows from investing activities - -198125.00000M 393530.00M 292119.00M -2835698.00000M
Net borrowings -285071.00000M -600477.00000M -660504.00000M -586090.00000M 3161504.00M
Total cash from financing activities -709148.00000M -1070265.00000M -1088354.00000M -1005213.00000M 2946237.00M
Change to operating activities 63568.00M -66289.00000M 260285.00M 44458.00M -26284.00000M
Net income 317038.00M 230166.00M 376171.00M 44290.00M 109014.00M
Change in cash -316165.00000M -116527.00000M 328608.00M -65108.00000M 407120.00M
Begin period cash flow 849695.00M 966222.00M 637614.00M 702722.00M 294973.00M
End period cash flow 533530.00M 849695.00M 966222.00M 637614.00M 702093.00M
Total cash from operating activities 977156.00M 1123105.00M 1010931.00M 669752.00M 328479.00M
Issuance of capital stock - - - - -
Depreciation 664400.00M 583151.00M 559671.00M 583649.00M 272446.00M
Other cashflows from investing activities 5564.00M -1007.00000M -8851.00000M -1256.00000M 73318.00M
Dividends paid -279416.00000M -283665.00000M -283357.00000M -282582.00000M 142952.00M
Change to inventory -79155.00000M -46148.00000M 25978.00M 137492.00M 58678.00M
Change to account receivables - 127294.00M -9316.00000M -34826.00000M -13382.00000M
Sale purchase of stock -26929.00000M -77531.00000M -2141.00000M -3737.00000M -1172.00000M
Other cashflows from financing activities -2732.00000M 140742.00M 1037163.00M 12163.00M 3092102.00M
Change to netincome 21003.00M 169881.00M -238312.00000M -75330.00000M -49042.00000M
Capital expenditures 633689.00M 186037.00M 236468.00M 217710.00M 134114.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -25264.00000M 98605.00M 275781.00M 94672.00M 75946.00M
Stock based compensation 60672.00M 43374.00M 37663.00M 29122.00M 20084.00M
Other non cash items -97742.00000M 95404.00M -228419.00000M 23063.00M -134893.00000M
Free cash flow 343467.00M 937068.00M 774463.00M 452042.00M 194365.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TKPHF
Takeda Pharmaceutical Co. Ltd.		 - -% 25.38 32.60 11.59 0.01 0.88 0.02 0.07
ZTS
Zoetis Inc		 -2.975 1.78% 164.03 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.12 0.42% 28.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.925 1.33% 142.50 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.07 0.53% 13.04 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co. Ltd.

1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668

Key Executives

Name Title Year Born
Mr. Christophe Weber Pres, CEO & Representative Director 1966
Mr. Constantine Saroukos CFO & Representative Director 1971
Dr. Andrew S. Plump Pres of R&D and Representative Director 1965
Dr. Seigo Izumo Chair of Management Board NA
Mr. Haruhiko Hirate Member of Management Board 1957
Salvatore Alesci Member of Management Board and Head of R&D Global Science & Biomedical Policy NA
Norimasa Takeda Chief Accounting Officer & Corp. Controller NA
Mr. Iwaaki Taniguchi Sr. VP of Corp. Fin. & Controlling Department NA
Mr. Gabriele Ricci Chief Data & Technology Officer 1978
Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Fin. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.